N Goldfarb1,2, M A Lowes3, M Butt4, T King4, A Alavi5, J S Kirby4. 1. Departments of Medicine and Dermatology, University of Minnesota, Minneapolis, MN, USA. 2. Departments of Medicine and Dermatology, Minneapolis Veteran Affairs Health Care System, Minneapolis, MN, USA. 3. The Rockefeller University, New York, NY, USA. 4. Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. 5. Department of Medicine, Division of Dermatology, Women's College Hospital, University of Toronto, Toronto, Canada.
Abstract
BACKGROUND: Validated, reliable, globally accepted outcome measurement instruments for hidradenitis suppurativa (HS) are needed. Current tools to measure the physical signs domain for HS rely on lesion counts, which are time-consuming and unreliable. OBJECTIVES: To assess the reliability and validity of the Hidradenitis suppurativa Area and Severity Index Revised (HASI-R) tool, a novel method for assessing HS severity, incorporating signs of inflammation and body surface area involved. METHODS: The measurement properties of the HASI-R tool were evaluated. The tool was created by combining the previously published HASI and Severity and Area Score for Hidradenitis instruments. Twenty raters evaluated 15 patients with HS in a hospital-based ambulatory dermatology clinic. The objectives of the study were to assess inter- and intra-rater reliability of the HASI-R and its components, as well as its construct and known-groups validity. Existing lesion count-based clinician-reported measures of HS and their components were also assessed. Raters were also asked their preferences regarding the various HS severity assessment tools. RESULTS: The HASI-R had moderate inter-rater reliability [intra-class correlation coefficients (ICC) 0·60]. This was better than all other HS physical sign outcome measures evaluated, which had poor inter-rater reliability (ICC < 0·5). HASI-R had the highest intra-rater reliability (ICC 0·91). The HASI-R had good construct validity and demonstrated known-groups validity. The HASI-R was also the most preferred tool by all raters. CONCLUSIONS: Results from the clinometric assessment of the HASI-R are encouraging, and support continued evaluation of this clinician-reported outcome measure.
BACKGROUND: Validated, reliable, globally accepted outcome measurement instruments for hidradenitis suppurativa (HS) are needed. Current tools to measure the physical signs domain for HS rely on lesion counts, which are time-consuming and unreliable. OBJECTIVES: To assess the reliability and validity of the Hidradenitis suppurativa Area and Severity Index Revised (HASI-R) tool, a novel method for assessing HS severity, incorporating signs of inflammation and body surface area involved. METHODS: The measurement properties of the HASI-R tool were evaluated. The tool was created by combining the previously published HASI and Severity and Area Score for Hidradenitis instruments. Twenty raters evaluated 15 patients with HS in a hospital-based ambulatory dermatology clinic. The objectives of the study were to assess inter- and intra-rater reliability of the HASI-R and its components, as well as its construct and known-groups validity. Existing lesion count-based clinician-reported measures of HS and their components were also assessed. Raters were also asked their preferences regarding the various HS severity assessment tools. RESULTS: The HASI-R had moderate inter-rater reliability [intra-class correlation coefficients (ICC) 0·60]. This was better than all other HS physical sign outcome measures evaluated, which had poor inter-rater reliability (ICC < 0·5). HASI-R had the highest intra-rater reliability (ICC 0·91). The HASI-R had good construct validity and demonstrated known-groups validity. The HASI-R was also the most preferred tool by all raters. CONCLUSIONS: Results from the clinometric assessment of the HASI-R are encouraging, and support continued evaluation of this clinician-reported outcome measure.
Authors: A Martorell; F Alfageme Roldán; E Vilarrasa Rull; R Ruiz-Villaverde; J Romaní De Gabriel; F García Martínez; D Vidal Sarro; M Velasco Pastor; C Ciudad Blanco; J M Segura Palacios; A I Rodríguez Bandera; J C Pascual Ramírez; C Sancho Sánchez; N Michelena De Gorosábel; X Wortsman Journal: J Eur Acad Dermatol Venereol Date: 2019-06-23 Impact factor: 6.166
Authors: L Thorlacius; A Garg; P T Riis; S M Nielsen; V Bettoli; J R Ingram; V Del Marmol; L Matusiak; J C Pascual; J Revuz; K Sartorius; T Tzellos; H H van der Zee; C C Zouboulis; D M Saunte; A B Gottlieb; R Christensen; G B E Jemec Journal: Br J Dermatol Date: 2019-06-06 Impact factor: 9.302
Authors: C C Zouboulis; N Desai; L Emtestam; R E Hunger; D Ioannides; I Juhász; J Lapins; L Matusiak; E P Prens; J Revuz; S Schneider-Burrus; J C Szepietowski; H H van der Zee; G B E Jemec Journal: J Eur Acad Dermatol Venereol Date: 2015-01-30 Impact factor: 6.166
Authors: Dan Lipsker; François Severac; Marie Freysz; Eric Sauleau; Jurr Boer; Lennart Emtestam; Łukasz Matusiak; Errol Prens; Charles Velter; Cédric Lenormand; Nicolas Meyer; Gregor B E Jemec Journal: Dermatology Date: 2016-02-19 Impact factor: 5.366
Authors: Alexa B Kimball; Martin M Okun; David A Williams; Alice B Gottlieb; Kim A Papp; Christos C Zouboulis; April W Armstrong; Francisco Kerdel; Michael H Gold; Seth B Forman; Neil J Korman; Evangelos J Giamarellos-Bourboulis; Jeffrey J Crowley; Charles Lynde; Ziad Reguiai; Errol-Prospero Prens; Eihab Alwawi; Nael M Mostafa; Brett Pinsky; Murali Sundaram; Yihua Gu; Dawn M Carlson; Gregor B E Jemec Journal: N Engl J Med Date: 2016-08-04 Impact factor: 91.245
Authors: Alison H Kohn; Afsaneh Alavi; April W Armstrong; Folawiyo Babalola; Amit Garg; Alice B Gottlieb; Lesley Grilli; Gregor Borut Ernst Jemec; John Latella; Kendall Marcus; Joseph F Merola; Alex G Ortega-Loayza; Daniel M Siegel; Vibeke Strand; Jerry K L Tan; Lourdes M Perez-Chada Journal: Dermatology Date: 2021-09-17 Impact factor: 5.197
Authors: Samuel Der Sarkissian; Schapoor Hessam; Joslyn S Kirby; Michelle A Lowes; Dillon Mintoff; Haley B Naik; Hans Christian Ring; Nisha Suyien Chandran; John W Frew Journal: JAMA Dermatol Date: 2022-03-01 Impact factor: 11.816
Authors: Piotr K Krajewski; Servando E Marrón; Lucía Tomas Aragones; Yolanda Gilaberte-Calzada; Jacek C Szepietowski Journal: Dermatol Ther (Heidelb) Date: 2022-03-10